[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"GE Healthcare Finland Oy\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":78},{"warningLetters":4,"total":77},[5,33,52],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1223,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-24T04:00:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024\">MMC Healthcare Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-62\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nageswara Rao Gupta Manepalli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MMC Healthcare Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-B Sidco Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thirumazhisai, Chennai\u003C\u002Fspan> \u003Cspan>600124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@mmchealthcareltd.com\"> ceo@mmchealthcareltd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-62\u003C\u002Fp>\n\n\u003Cp>September 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Manepalli:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 18, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility our Investigator observed that your 2021 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research &amp; Development Manager, and Production Manager admitted to participating in these practices.\u003C\u002Fp>\n\n\u003Cp>Review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Capsules \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\u003C\u002Fp>\n\n\u003Cp>Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not provide sufficient details describing:\u003C\u002Fp>\n\n\u003Cp>• Timeframe for your corrective action.\u003Cbr>\n• Security features of your updated UV-Vis computer system.\u003Cbr>\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003Cbr>\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\u003Cbr>\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; o An evaluation of the impact of this violation.\u003Cbr>\n&nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; o A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; o System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; o Timeline for the implementation and qualification of your updated UV-Vis software.\u003Cbr>\n&nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; o Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; o Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your \u003Cem>E. coli\u003C\u002Fem> test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\u003C\u002Fp>\n\n\u003Cp>Test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution within expiry using the revised method, all of which passed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 6, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-62\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nageswara Rao Gupta Manepalli\n\nRecipient Title\n\nManaging Director\u002FCEO\n\nMMC Healthcare Ltd.\n\n34-B Sidco Industrial Estate\n\nThirumazhisai, Chennai 600124\n\nTamil Nadu\n\nIndia\n\nceo@mmchealthcareltd.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-62\n\nSeptember 24, 2024\n\nDear Mr. Manepalli:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 18, 2024 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nDuring the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research & Development Manager, and Production Manager admitted to participating in these practices.\n\nReview of the (b)(4) Capsules (b)(4) mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\n\nIn your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\n\nYour response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\n\nData integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nIn your response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\n\nIn your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\n\nYour response is inadequate because it does not provide sufficient details describing:\n\n• Timeframe for your corrective action.\n\n• Security features of your updated UV-Vis computer system.\n\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\n\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\n\nIt is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\n\no An evaluation of the impact of this violation.\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Timeline for the implementation and qualification of your updated UV-Vis software.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your E. coli test method for (b)(4) Solution and (b)(4) Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\n\nTest methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\n\nIn your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of (b)(4) Solution within expiry using the revised method, all of which passed.\n\nYour response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 6, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nArticles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","MMC Healthcare Ltd.","mmc-healthcare-ltd-684644-09242024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024","2026-10-26T08:09:26.775337+00:00","Warning Letter","Issued","2024-10-08","684644","Drugs","Mr. Nageswara Rao Gupta Manepalli","2026-08-19T22:31:41.964+00:00","Via Email","320-24-62","2024-09-24",{"id":34,"raw":35,"subject":14,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":27,"closeout_date":20,"issuing_office":39,"recipient_name":49,"body_fetched_at":50,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":51,"medical_device_id":20,"response_letter_date":20},1966,[36,37,38,39,14,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023\">Baxter Healthcare Corporation\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José E. Almeida\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, CEO and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baxter Healthcare Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Baxter Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Deerfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-18\u003C\u002Fp>\n\n\u003Cp>July 25, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Almeida:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm did not adequately investigate failures of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine to inspect commercially distributed products (e.g., several batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Challenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles despite their lower detectability than other “dark” particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber glass vials. The challenge also used a highly detectable particle range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> μm, but still indicated detection and capability issues. Similar challenges to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> automatic inspection machine were free from visible particulates.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>In your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\u003C\u002Fp>\n\n\u003Cp>However, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\u003C\u002Fp>\n\n\u003Cp>We encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An FDA investigator observed white spots at the bottom of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as \u003Cstrong>(b)(4)\u003C\u002Fstrong> (the product previously processed on this equipment) at levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> parts per million (ppm). Your limit for post-cleaning residues is not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Your response noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, not \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Personnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\u003C\u002Fli>\n\t\u003Cli>You lacked scientific justification for removing vials containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles from the defect kits used to qualify visual inspection processes. For example, although \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles were more difficult to reproducibly detect than \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL amber vials, you elected to only use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stopper particles in the defect kits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Equipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you commit to replacing the threaded bolt \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a \u003Cstrong>(b)(4)\u003C\u002Fstrong> conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Process Controls\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\u003Cbr>\n(rishikesh_jaiwant@baxter.com)\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José E. Almeida\n\nRecipient Title\n\nChairman, CEO and President\n\nBaxter Healthcare Corporation\n\n1 Baxter Parkway\n\nDeerfield, IL 60015\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-18\n\nJuly 25, 2023\n\nDear Mr. Almeida:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, India, from January 19 to January 27, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 17, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to conduct adequate investigations into endotoxin testing and your 100% automated visual inspection system. You conducted investigations that were not thorough, expanded to an appropriate scope, or based on scientifically supported root cause(s). You did not identify and implement appropriate corrective actions and preventive actions (CAPA). Specifically,\n\nYour firm invalidated multiple endotoxin tests for finished products upon discovery of particulate matter in one or more wells used to perform the kinetic-turbidimetric assay (KTA) method. You failed to characterize the particulate matter and attributed the particulates to environmental and laboratory conditions, such as air ducts and activities being performed by personnel in the immediate vicinity of the analysis. You did not definitively identify the source or sources of the particulate matter, define the scope of potentially impacted operations (including potential manufacturing causes), and implement scientifically justified CAPA in a timely manner.\n\nIn a previous inspection (May 2022), FDA cited your firm for inadequate investigations into these and other similar out-of-specification (OOS) endotoxin testing that you invalidated due to uncharacterized particulate contamination in one or more wells during KTA analyses. Prior to and during an October 5, 2022 regulatory meeting with your firm, we requested you perform a retrospective assessment of investigations associated with OOS endotoxin results or endotoxin testing deviations. During the current inspection, your personnel explained that these investigations were not reopened or otherwise reassessed. Although you retained a third-party consultant to perform a retrospective assessment of endotoxin investigations associated with OOS endotoxin result investigations, you did not provide the third-party consultant with an investigation cited during the May 2022 inspection. You also did not ensure the assessment included approximately 20 invalidated laboratory tests generated in 2021 and 2022 (including multiple investigations since the May 2022 inspection).\n\nYour firm did not adequately investigate failures of the (b)(4) automatic inspection machine to detect known defects, including particulate matter in injectable drug products. Despite the data indicating significant deficiencies in the machine’s ability to detect known defects during its use, you continued to employ the (b)(4) automatic inspection machine to inspect commercially distributed products (e.g., several batches of (b)(4) injection (b)(4) mg\u002FmL USP). Notably, you fully relied on this automated visual inspection system to detect various defects including particulate contamination for an extended period and did not perform a 100% manual visual inspection for all defects.\n\nChallenges with defect kits indicated failing rejection rates or other deficiencies. For example, an October 2022 challenge excluded the use of (b)(4) particles despite their lower detectability than other “dark” particles in (b)(4) mL amber glass vials. The challenge also used a highly detectable particle range of (b)(4) μm, but still indicated detection and capability issues. Similar challenges to the (b)(4) automatic inspection machine utilized commercial inspection parameters. You did not initiate adequate investigations into these detection issues. You lacked adequate assurance that sterile injectable drug batches visually inspected with the (b)(4) automatic inspection machine were free from visible particulates.\n\nYour response is inadequate. Your firm previously committed to evaluate and implement improvements to your procedures and practices associated with the conduct of investigations following the conclusion of the July 27 to August 4, 2017, inspection of this facility and in response to the warning letter sent to your firm on July 5, 2018. You also reported significant CAPA activities to address the frequency of endotoxin testing OOS results and deviations following the October 5, 2022, regulatory meeting.\n\nIn your February 17, 2023, response to the Form FDA 483 issued at the conclusion of the most recent inspection, you commit to further revisions of your investigation procedures.\n\nHowever, you do not adequately address your failure to conduct timely investigations into recurring and persistent issues. Your response did not adequately address the use of insufficiently qualified (b)(4) equipment for 100% visual inspection of injectable drug products for approximately five years (until October 2022) and the excessive number of samples contaminated with endotoxins or particles in your laboratory.\n\nWe encourage the use of automated visual inspection for particulates to augment the 100% manual visual inspection program. Automated methods should be rigorously studied for their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, and other variables. In addition, any use of automated particulate inspection does not supplant the need for 100% manual visual inspection for various other attributes (e.g., cracks).\n\nIn response to this letter, provide:\n\nA written commitment to have all lots of finished products manufactured at your facility analyzed for endotoxins by a qualified laboratory until you have thoroughly investigated each endotoxin test invalidation event since January 1, 2018, and implemented all necessary CAPA to prevent recurrence of endotoxin result invalidations. This should include but not be limited to assuring CAPA effectiveness for your particulate and pipetting issues.\n\nA comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter, used for products distributed in the United States that remain within expiry. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation and the procedures governing them. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness.\n\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA third-party protocol and the executed protocol final report for the retrospective review of particulate matter investigations associated with distributed in the United States that remain within expiry, irrespective of whether the original investigation resulted in the invalidation of the original result. The protocol should include an evaluation of the investigation’s thoroughness; assignment and scientific justification for root cause(s); documentation of CAPA implementation, and documented effectiveness of CAPA.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nAn FDA investigator observed white spots at the bottom of a (b)(4) L bulk solution holding tank used to supply a non-dedicated filling machine despite the vessel being documented as clean. You subsequently analyzed and identified the white spots as (b)(4) (the product previously processed on this equipment) at levels of up to (b)(4) parts per million (ppm). Your limit for post-cleaning residues is not more than (b)(4) ppm.\n\nYour response is inadequate. Although you revised your cleaning procedure to require vessels to be dry before conducting the visual inspection for cleanliness and implemented visual verification of the vessel interior via a sight glass following the cleaning and (b)(4) activities, you did not provide scientific justification for your use of visual inspection to verify the removal of residues to levels as low as (b)(4) ppm. Your response noted (b)(4) injection, not (b)(4) injection, is the “worst-case product” processed in this vessel, but you did not provide a comprehensive investigation to assess the impact of this cleaning deviation on products previously manufactured on this and other non-dedicated equipment. You also did not propose a systemic assessment of your equipment cleaning program.\n\nIn response to this letter, provide:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nYour program for the visual inspection of sterile injectable drug products does not provide adequate assurance that finished products manufactured at your facility possess their purported quality attributes, including that they are free from particulate matter. For example,\n\nPersonnel performed 100% manual visual inspection of sterile injectable units for less than the minimum amount of time required by your written procedures.\n\nYou lacked scientific justification for removing vials containing (b)(4) particles from the defect kits used to qualify visual inspection processes. For example, although (b)(4) particles were more difficult to reproducibly detect than (b)(4) stopper particles in the (b)(4) mL amber vials, you elected to only use the (b)(4) stopper particles in the defect kits.\n\nYour response is inadequate. You commit to using a “pacing device” during the 100% manual visual inspections and requiring a supervisor to periodically verify the inspection times. You did not provide a description of the pacing device or commit to requalify operators following implementation of the pacing device. Additionally, you did not commit to evaluate operator performance throughout a (b)(4).\n\nYou also state a successful qualification program does not evaluate “… an inspector’s ability to differentiate and identify various types and morphologies of particles.” However, it is critical to be able to reproducibly detect particulate defects of different types, morphologies, and sizes.\n\nIn response to this letter, provide a comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility to the United States that remains within expiry to meet the requirement of being essentially free of visible particles. The assessment should also include consideration of gaps and other deficiencies identified in the independent assessment of your systems for visual inspection of sterile injectable drugs.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\n\nEquipment used in the manufacture of terminally sterilized drugs at your facility is not designed or maintained appropriately. Our inspection revealed instances of damaged metal and plastic parts, open vials exposed to worn bolt threading, and process flow that required employees to duck underneath the sterile processing line conveyer in order to perform interventions near open vials (e.g., stopper addition on the (b)(4) filling line).\n\nYour response is inadequate. Although you commit to replacing the threaded bolt (b)(4) on the (b)(4) filling line with a different part that will not expose a threading over open vials, you did not commit to evaluate production rooms and production equipment for wear, damage, or poor design that may lead to the generation of particulate matter in the vicinity of open vials. You also plan to install a (b)(4) conveyor at the capping machine outfeed, and merge filling and capping areas, for two filling lines ((b)(4) and (b)(4)), but you did not commit to perform a comprehensive assessment of your facility’s production lines to ensure they are appropriately designed and controlled.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of the design of each sterile drug production line, including facility layout, equipment placement and ergonomics, and personnel and material flow. Provide your detailed remediation plan with timelines to address the findings of the assessment. Describe specific tangible improvements to be made to the sterile processing operation design and control. Include a plan to assess the effectiveness of the improvements.\n\nA comprehensive, independent assessment of the condition of equipment including change parts, and the procedures and practices associated with equipment maintenance. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and periodic assessment of the plan’s effectiveness.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production oversight, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\n\nProcess Controls\n\nYour firm does not have an adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FProcess-Validation--General-Principles-and-Practices.pdf.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 and independent of your firm to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Baxter Pharmaceuticals India Pvt. Ltd., 3004610460, at Village Vasana Chacharwadi, Taluka Sanand, Ahmedabad, Gujarat, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nWe request you email Temeka Moore, Temeka.Moore@fda.hhs.gov, within five days of receipt of this letter to schedule a regulatory meeting.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004610460 and ATTN: Jason F. Chancey.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc: Rishikesh Jaiwant, Senior Director Manufacturing and Operations- Ahmedabad\n\n(rishikesh_jaiwant@baxter.com)\n\n_________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Baxter Healthcare Corporation","baxter-healthcare-corporation-654136-07252023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-healthcare-corporation-654136-07252023","2026-10-26T08:08:01.800292+00:00","2023-08-01","654136","Mr. José E. Almeida","2026-08-20T00:49:44.234+00:00","2023-07-25",{"id":53,"raw":54,"subject":59,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":20,"letter_url":66,"updated_at":67,"action_type":23,"case_status":68,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":72,"issuing_office":58,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":20,"reference_number":20,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},2978,[55,56,57,58,59,13,60,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-23T05:00:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021\">DeVilbiss Healthcare LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Operations (Division 1)","Medical Device Reporting\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrive-devilbiss-healthcare-llc-619182-10232024\">\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Derek Lampert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DeVilbiss Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>99 Seaview Blvd, Suite 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Washington\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Operations (Division 1)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Lampert:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. &nbsp;During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. &nbsp;Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. &nbsp;We address the responses below, in relation to each of the noted violations. &nbsp;These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). &nbsp;Specifically,\u003C\u002Fp>\n\n\u003Cp>The model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (5°C-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C). &nbsp;Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We reviewed your responses for this matter and conclude that they are not adequate. &nbsp;In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. &nbsp;You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” &nbsp;Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. &nbsp;This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\u003C\u002Fp>\n\n\u003Cp>Included in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C ambient temperature is one of the stress factors used in the study. &nbsp;This would demonstrate not that \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Protocol and Report.” &nbsp;The test of compressor temperatures ran for a duration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that were higher than the manufacturer’s specified temperature for the compressors. &nbsp;The 525 Oxygen Concentrator is typically run for much longer periods of time than only \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in possible temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong> that could result in much higher ambient temperatures over time. &nbsp;The test of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include any definition of a time element in the test method or results. &nbsp;It cannot be determined the duration of the test, or how often data readings were taken.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” &nbsp;The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. &nbsp;Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. &nbsp;Examples include:&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;RO_0264829, received on 04\u002F02\u002F2020\u003Cbr>\n­ RO_0252308, received on 1\u002F28\u002F2020\u003Cbr>\n­ RO_0208546, received on 04\u002F05\u002F2019\u003Cbr>\n­ RO_0180765, received on 08\u002F23\u002F2018\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” &nbsp;No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. &nbsp;No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n3.&nbsp;&nbsp; &nbsp;Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is trending in a direction that could lead to a potential undesirable event.” &nbsp;No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> “trending in a direction that could lead to a potential undesirable event.”\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. &nbsp;Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. &nbsp;It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. &nbsp;Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. &nbsp;The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp;&nbsp; &nbsp;Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). &nbsp;Specifically, you do not have a written procedure that governs rework for in-process products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. &nbsp;Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR). &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>6.&nbsp;&nbsp; &nbsp;Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). &nbsp;Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. &nbsp;Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7.&nbsp;&nbsp; &nbsp;Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>On 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. &nbsp;These corrective actions are ongoing at this time.\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure, injunction, and civil money penalties. &nbsp;Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. &nbsp;Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address all violations included in this Warning Letter.&nbsp;\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. &nbsp;Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nJoseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>cc: &nbsp;&nbsp; &nbsp;Joseph Lewarski, Senior Vice President, Clinical Affairs\u003Cbr>\n&nbsp;&nbsp; &nbsp;Tony Sapp, Director, Regulatory Affairs and Audits\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDerek Lampert\n\nRecipient Title\n\nChief Executive Officer\n\nDeVilbiss Healthcare LLC\n\n99 Seaview Blvd, Suite 210\n\nPort Washington, NY 11050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Operations (Division 1)\n\nUnited States\n\nDear Mr. Lampert:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). Specifically,\n\nThe model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-(b)(4)°F (5°C-(b)(4)°C). Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in (b)(4) of the (b)(4) measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites.\n\nWe reviewed your responses for this matter and conclude that they are not adequate. In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of (b)(4)°C. You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\n\nIncluded in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at (b)(4)°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. The (b)(4)°C ambient temperature is one of the stress factors used in the study. This would demonstrate not that (b)(4)°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.\n\nIn your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “(b)(4) Test Protocol and Report.” The test of compressor temperatures ran for a duration of (b)(4) and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the (b)(4) period that were higher than the manufacturer’s specified temperature for the compressors. The 525 Oxygen Concentrator is typically run for much longer periods of time than only (b)(4), resulting in possible temperature (b)(4) that could result in much higher ambient temperatures over time. The test of (b)(4) did not include any definition of a time element in the test method or results. It cannot be determined the duration of the test, or how often data readings were taken.\n\nPlease provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range.\n\n2. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. Examples include, but are not limited to:\n\n• Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”\n\n• Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. Examples include:\n\nRO_0264829, received on 04\u002F02\u002F2020\n\n­ RO_0252308, received on 1\u002F28\u002F2020\n\n­ RO_0208546, received on 04\u002F05\u002F2019\n\n­ RO_0180765, received on 08\u002F23\u002F2018\n\n• Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\n\n• Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event.\n\n3. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that (b)(4) is trending in a direction that could lead to a potential undesirable event.” No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a (b)(4) “trending in a direction that could lead to a potential undesirable event.”\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.\n\nPlease provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\n\n4. Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\n\n• Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\n\n5. Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Specifically, you do not have a written procedure that governs rework for in-process products.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR).\n\nPlease provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\n\nOur inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n6. Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints.\n\nPlease provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements.\n\n7. Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Specifically,\n\nOn 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4). An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing.\n\nYou also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. These corrective actions are ongoing at this time.\n\nPlease provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nAdditionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002Fs\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\ncc: Joseph Lewarski, Senior Vice President, Clinical Affairs\n\nTony Sapp, Director, Regulatory Affairs and Audits","DeVilbiss Healthcare LLC","devilbiss-healthcare-llc-619182-11232021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021","2026-10-26T08:08:23.773628+00:00","Closed Out","2021-12-14","619182","Medical Devices","2024-10-30","Derek Lampert","2026-08-20T02:20:42.968+00:00","UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL","2021-11-23",3,{"510k":79,"classification":80,"enforcement":81,"event":82,"event_backfill":83,"pma":84,"warning_letter":85},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]